While increased expression of Pyk2 stimulated glioma cell migration in a dose-dependent manner, knockdown of Pyk2 expression by shRNA significantly inhibited glioma cell migration in vitro, invasion ex vivo, and increased survival of intracranial xenografts in vivo [9, 10]. Here, PTK2B is linked to central nervous system cancer.